Skip to main content
Erschienen in: Digestive Diseases and Sciences 4/2023

29.09.2022 | Original Article

Prepandemic Prevalence Estimates of Fatty Liver Disease and Fibrosis Defined by Liver Elastography in the United States

verfasst von: Aynur Unalp-Arida, Constance E. Ruhl

Erschienen in: Digestive Diseases and Sciences | Ausgabe 4/2023

Einloggen, um Zugang zu erhalten

Abstract

Background and Aims

Fatty liver disease is a growing public health burden. We estimated prepandemic fatty liver disease prevalence determined by transient elastography-assessed hepatic steatosis and fibrosis, and examined associations with lifestyle and other factors in a United States population sample.

Methods

Liver stiffness and controlled attenuation parameter (CAP) were assessed on 7923 non-Hispanic white, non-Hispanic black, non-Hispanic Asian, and Hispanic men and women aged 20 years and over in the National Health and Nutrition Examination Survey (NHANES) 2017–March 2020 prepandemic data.

Results

The prevalence of fatty liver disease (CAP > 300 dB/m) was 28.8% and of fibrosis (liver stiffness > 8 kPa) was 10.4%. Only 7.2% of participants with fatty liver disease and 10.9% with fibrosis reported being told by a health care provider that they had liver disease. In addition to known risk factors such as metabolic factors and ALT, persons with fatty liver disease were less likely to meet physical activity guidelines, more likely to be sedentary for ≥ 12 h a day, and reported a less healthy diet. Persons with fibrosis were less likely to have a college degree and reported a less healthy diet.

Conclusions

In the U.S. population, most persons with fatty liver disease are unaware of their condition. Physical activity and dietary modifications might reduce the fatty liver disease burden. There is an urgent need for fatty liver disease management in high-risk individuals using transient elastography or other noninvasive methods to intervene in disease progression.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Peery AF, Crockett SD, Murphy CC et al. Burden and cost of gastrointestinal, liver, and pancreatic diseases in the United States: Update 2021. Gastroenterology. 2022;162:621–644.PubMedCrossRef Peery AF, Crockett SD, Murphy CC et al. Burden and cost of gastrointestinal, liver, and pancreatic diseases in the United States: Update 2021. Gastroenterology. 2022;162:621–644.PubMedCrossRef
2.
Zurück zum Zitat Xu JQ, Murphy SL, Kochanek KD, Arias E. Deaths: Final data for 2019. National Vital Statistics Reports; vol 70 no 08. Hyattsville, MD: National Center for Health Statistics; 2021.CrossRef Xu JQ, Murphy SL, Kochanek KD, Arias E. Deaths: Final data for 2019. National Vital Statistics Reports; vol 70 no 08. Hyattsville, MD: National Center for Health Statistics; 2021.CrossRef
3.
Zurück zum Zitat Unalp-Arida A, Ruhl CE. Noninvasive fatty liver markers predict liver disease mortality in the U.S. population. Hepatology. 2016;63:1170–1183.PubMedCrossRef Unalp-Arida A, Ruhl CE. Noninvasive fatty liver markers predict liver disease mortality in the U.S. population. Hepatology. 2016;63:1170–1183.PubMedCrossRef
4.
Zurück zum Zitat Sanyal AJ, Van Natta ML, Clark J et al. NASH clinical research network (CRN). Prospective study of outcomes in adults with nonalcoholic fatty liver disease. N Engl J Med. 2021;385:1559–1569.PubMedPubMedCentralCrossRef Sanyal AJ, Van Natta ML, Clark J et al. NASH clinical research network (CRN). Prospective study of outcomes in adults with nonalcoholic fatty liver disease. N Engl J Med. 2021;385:1559–1569.PubMedPubMedCentralCrossRef
5.
Zurück zum Zitat Kanwal F, Shubrook JH, Younossi Z et al. Preparing for the NASH epidemic: A call to action. Gastroenterology. 2021;161:1030–1042.PubMedCrossRef Kanwal F, Shubrook JH, Younossi Z et al. Preparing for the NASH epidemic: A call to action. Gastroenterology. 2021;161:1030–1042.PubMedCrossRef
6.
Zurück zum Zitat Kanwal F, Shubrook JH, Adams LA et al. Clinical care pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease. Gastroenterology. 2021;161:1657–1669.PubMedCrossRef Kanwal F, Shubrook JH, Adams LA et al. Clinical care pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease. Gastroenterology. 2021;161:1657–1669.PubMedCrossRef
7.
Zurück zum Zitat Eslam M, Newsome PN, Sarin SK et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol. 2020;73:202–209.PubMedCrossRef Eslam M, Newsome PN, Sarin SK et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol. 2020;73:202–209.PubMedCrossRef
8.
Zurück zum Zitat Ciardullo S, Perseghin G. Prevalence of NAFLD, MAFLD and associated advanced fibrosis in the contemporary United States population. Liver Int. 2021;41:1290–1293.PubMedCrossRef Ciardullo S, Perseghin G. Prevalence of NAFLD, MAFLD and associated advanced fibrosis in the contemporary United States population. Liver Int. 2021;41:1290–1293.PubMedCrossRef
9.
Zurück zum Zitat van Kleef LA, Ayada I, Alferink LJM, Pan Q, de Knegt RJ. Metabolic dysfunction-associated fatty liver disease improves detection of high liver stiffness: The Rotterdam Study. Hepatology. 2022;75:419–429.PubMedCrossRef van Kleef LA, Ayada I, Alferink LJM, Pan Q, de Knegt RJ. Metabolic dysfunction-associated fatty liver disease improves detection of high liver stiffness: The Rotterdam Study. Hepatology. 2022;75:419–429.PubMedCrossRef
10.
Zurück zum Zitat Wong VW, Wong GL, Woo J et al. Impact of the new definition of metabolic associated fatty liver disease on the epidemiology of the disease. Clin Gastroenterol Hepatol. 2021;19:2161–2171.PubMedCrossRef Wong VW, Wong GL, Woo J et al. Impact of the new definition of metabolic associated fatty liver disease on the epidemiology of the disease. Clin Gastroenterol Hepatol. 2021;19:2161–2171.PubMedCrossRef
11.
Zurück zum Zitat Younossi ZM, Corey KE, Lim JK. AGA clinical practice update on lifestyle modification using diet and exercise to achieve weight loss in the management of nonalcoholic fatty liver disease: Expert review. Gastroenterology. 2021;160:912–918.PubMedCrossRef Younossi ZM, Corey KE, Lim JK. AGA clinical practice update on lifestyle modification using diet and exercise to achieve weight loss in the management of nonalcoholic fatty liver disease: Expert review. Gastroenterology. 2021;160:912–918.PubMedCrossRef
12.
Zurück zum Zitat Kim D, Konyn P, Cholankeril G, Ahmed A. Physical activity is associated with nonalcoholic fatty liver disease and significant fibrosis measured by fibroscan. Clin Gastroenterol Hepatol. 2022;20:e1438–e1455.PubMedCrossRef Kim D, Konyn P, Cholankeril G, Ahmed A. Physical activity is associated with nonalcoholic fatty liver disease and significant fibrosis measured by fibroscan. Clin Gastroenterol Hepatol. 2022;20:e1438–e1455.PubMedCrossRef
14.
Zurück zum Zitat Heredia NI, Zhang X, Balakrishnan M et al. Physical activity and diet quality in relation to non-alcoholic fatty liver disease: A cross-sectional study in a representative sample of US adults using NHANES 2017–2018. Prev Med. 2022;154:106903.PubMedCrossRef Heredia NI, Zhang X, Balakrishnan M et al. Physical activity and diet quality in relation to non-alcoholic fatty liver disease: A cross-sectional study in a representative sample of US adults using NHANES 2017–2018. Prev Med. 2022;154:106903.PubMedCrossRef
16.
Zurück zum Zitat Sasso M, Miette V, Sandrin L, Beaugrand M. The controlled attenuation parameter (CAP): A novel tool for the non-invasive evaluation of steatosis using Fibroscan®. Clin Res Hepatol Gastroenterol. 2012;36:13–20.PubMedCrossRef Sasso M, Miette V, Sandrin L, Beaugrand M. The controlled attenuation parameter (CAP): A novel tool for the non-invasive evaluation of steatosis using Fibroscan®. Clin Res Hepatol Gastroenterol. 2012;36:13–20.PubMedCrossRef
17.
Zurück zum Zitat Fabrellas N, Hernandez R, Graupera I et al. Prevalence of hepatic steatosis as assessed by controlled attenuation parameter (CAP) in subjects with metabolic risk factors in primary care. A population-based study. PLoS ONE. 2018;13:e0200656.PubMedPubMedCentralCrossRef Fabrellas N, Hernandez R, Graupera I et al. Prevalence of hepatic steatosis as assessed by controlled attenuation parameter (CAP) in subjects with metabolic risk factors in primary care. A population-based study. PLoS ONE. 2018;13:e0200656.PubMedPubMedCentralCrossRef
18.
Zurück zum Zitat Kim D, Cholankeril G, Loomba R, Ahmed A. Prevalence of fatty liver disease and fibrosis detected by transient elastography in adults in the United States, 2017–2018. Clin Gastroenterol Hepatol. 2021;19:1499–1501.PubMedCrossRef Kim D, Cholankeril G, Loomba R, Ahmed A. Prevalence of fatty liver disease and fibrosis detected by transient elastography in adults in the United States, 2017–2018. Clin Gastroenterol Hepatol. 2021;19:1499–1501.PubMedCrossRef
19.
Zurück zum Zitat Zhang X, Heredia NI, Balakrishnan M, Thrift AP. Prevalence and factors associated with NAFLD detected by vibration controlled transient elastography among US adults: Results from NHANES 2017–2018. PLoS ONE. 2021;16:e0252164.PubMedPubMedCentralCrossRef Zhang X, Heredia NI, Balakrishnan M, Thrift AP. Prevalence and factors associated with NAFLD detected by vibration controlled transient elastography among US adults: Results from NHANES 2017–2018. PLoS ONE. 2021;16:e0252164.PubMedPubMedCentralCrossRef
20.
Zurück zum Zitat Truong E, Yeo YH, Cook-Wiens G, et al. Nonalcoholic fatty liver disease prevalence and severity in Asian Americans from the national health and nutrition examination surveys 2017–2018. Hepatol Commun. 2022;6:2253–2261.PubMedPubMedCentralCrossRef Truong E, Yeo YH, Cook-Wiens G, et al. Nonalcoholic fatty liver disease prevalence and severity in Asian Americans from the national health and nutrition examination surveys 2017–2018. Hepatol Commun. 2022;6:2253–2261.PubMedPubMedCentralCrossRef
22.
Zurück zum Zitat Unalp-Arida A, Ruhl CE. Transient elastography-assessed hepatic steatosis and fibrosis are associated with body composition in the United States. Clin Gastroenterol Hepatol. 2022;20:e808–e830.PubMedCrossRef Unalp-Arida A, Ruhl CE. Transient elastography-assessed hepatic steatosis and fibrosis are associated with body composition in the United States. Clin Gastroenterol Hepatol. 2022;20:e808–e830.PubMedCrossRef
25.
Zurück zum Zitat Vuppalanchi R, Siddiqui MS, Van Natta ML et al. NASH clinical research network. Performance characteristics of vibration-controlled transient elastography for evaluation of nonalcoholic fatty liver disease. Hepatology. 2018;67:134–144.PubMedCrossRef Vuppalanchi R, Siddiqui MS, Van Natta ML et al. NASH clinical research network. Performance characteristics of vibration-controlled transient elastography for evaluation of nonalcoholic fatty liver disease. Hepatology. 2018;67:134–144.PubMedCrossRef
26.
Zurück zum Zitat Siddiqui MS, Vuppalanchi R, Van Natta ML et al. NASH clinical research network. Vibration-controlled transient elastography to assess fibrosis and steatosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2019;17:156–163.PubMedCrossRef Siddiqui MS, Vuppalanchi R, Van Natta ML et al. NASH clinical research network. Vibration-controlled transient elastography to assess fibrosis and steatosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2019;17:156–163.PubMedCrossRef
27.
Zurück zum Zitat Eddowes PJ, Sasso M, Allison M et al. Accuracy of FibroScan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology. 2019;156:1717–1730.PubMedCrossRef Eddowes PJ, Sasso M, Allison M et al. Accuracy of FibroScan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology. 2019;156:1717–1730.PubMedCrossRef
28.
Zurück zum Zitat Chalasani N, Younossi Z, Lavine JE et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67:328–357.PubMedCrossRef Chalasani N, Younossi Z, Lavine JE et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67:328–357.PubMedCrossRef
29.
Zurück zum Zitat Hosmer DW, Lemeshow S, Sturdivant RX. Applied Logistic Regression, 3rd edn. Hoboken, NJ: Wiley; 2013; 89–149. Hosmer DW, Lemeshow S, Sturdivant RX. Applied Logistic Regression, 3rd edn. Hoboken, NJ: Wiley; 2013; 89–149.
30.
Zurück zum Zitat Breslow NE, Day NE. Statistical Methods in Cancer Research: the Design and Analysis of Cohort Studies, Lyon: International Agency for Research on Cancer; 1987; 48–79. Breslow NE, Day NE. Statistical Methods in Cancer Research: the Design and Analysis of Cohort Studies, Lyon: International Agency for Research on Cancer; 1987; 48–79.
31.
Zurück zum Zitat Ciardullo S, Monti T, Perseghin G. High prevalence of advanced liver fibrosis assessed by transient elastography among U.S. adults with type 2 diabetes. Diabetes Care. 2021;44:519–525.PubMedCrossRef Ciardullo S, Monti T, Perseghin G. High prevalence of advanced liver fibrosis assessed by transient elastography among U.S. adults with type 2 diabetes. Diabetes Care. 2021;44:519–525.PubMedCrossRef
32.
Zurück zum Zitat Ginès P, Castera L, Lammert F et al. Population screening for liver fibrosis: Toward early diagnosis and intervention for chronic liver diseases. Hepatology. 2022;75:219–228.PubMedCrossRef Ginès P, Castera L, Lammert F et al. Population screening for liver fibrosis: Toward early diagnosis and intervention for chronic liver diseases. Hepatology. 2022;75:219–228.PubMedCrossRef
33.
Zurück zum Zitat Roulot D, Costes JL, Buyck JF et al. Transient elastography as a screening tool for liver fibrosis and cirrhosis in a community-based population aged over 45 years. Gut. 2011;60:977–984.PubMedCrossRef Roulot D, Costes JL, Buyck JF et al. Transient elastography as a screening tool for liver fibrosis and cirrhosis in a community-based population aged over 45 years. Gut. 2011;60:977–984.PubMedCrossRef
34.
Zurück zum Zitat Koehler EM, Plompen EP, Schouten JN et al. Presence of diabetes mellitus and steatosis is associated with liver stiffness in a general population: The Rotterdam study. Hepatology. 2016;63:138–147.PubMedCrossRef Koehler EM, Plompen EP, Schouten JN et al. Presence of diabetes mellitus and steatosis is associated with liver stiffness in a general population: The Rotterdam study. Hepatology. 2016;63:138–147.PubMedCrossRef
35.
Zurück zum Zitat Caballería L, Pera G, Arteaga I et al. High prevalence of liver fibrosis among European adults with unknown liver disease: A population-based study. Clin Gastroenterol Hepatol. 2018;16:1138–1145.PubMedCrossRef Caballería L, Pera G, Arteaga I et al. High prevalence of liver fibrosis among European adults with unknown liver disease: A population-based study. Clin Gastroenterol Hepatol. 2018;16:1138–1145.PubMedCrossRef
36.
Zurück zum Zitat Petta S, Di Marco V, Pipitone RM et al. Prevalence and severity of nonalcoholic fatty liver disease by transient elastography: Genetic and metabolic risk factors in a general population. Liver Int. 2018;38:2060–2068.PubMedCrossRef Petta S, Di Marco V, Pipitone RM et al. Prevalence and severity of nonalcoholic fatty liver disease by transient elastography: Genetic and metabolic risk factors in a general population. Liver Int. 2018;38:2060–2068.PubMedCrossRef
37.
Zurück zum Zitat Abeysekera KWM, Fernandes GS, Hammerton G et al. Prevalence of steatosis and fibrosis in young adults in the UK: A population-based study. Lancet Gastroenterol Hepatol. 2020;5:295–305.PubMedPubMedCentralCrossRef Abeysekera KWM, Fernandes GS, Hammerton G et al. Prevalence of steatosis and fibrosis in young adults in the UK: A population-based study. Lancet Gastroenterol Hepatol. 2020;5:295–305.PubMedPubMedCentralCrossRef
38.
Zurück zum Zitat Wong VW, Chu WC, Wong GL et al. Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: A population study using proton-magnetic resonance spectroscopy and transient elastography. Gut. 2012;61:409–415.PubMedCrossRef Wong VW, Chu WC, Wong GL et al. Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: A population study using proton-magnetic resonance spectroscopy and transient elastography. Gut. 2012;61:409–415.PubMedCrossRef
39.
Zurück zum Zitat Baba M, Furuya K, Bandou H, Kasai K, Sadaoka K. Discrimination of individuals in a general population at high-risk for alcoholic and non-alcoholic fatty liver disease based on liver stiffness: A cross section study. BMC Gastroenterol. 2011;13:70.CrossRef Baba M, Furuya K, Bandou H, Kasai K, Sadaoka K. Discrimination of individuals in a general population at high-risk for alcoholic and non-alcoholic fatty liver disease based on liver stiffness: A cross section study. BMC Gastroenterol. 2011;13:70.CrossRef
40.
Zurück zum Zitat You SC, Kim KJ, Kim SU et al. Factors associated with significant liver fibrosis assessed using transient elastography in general population. World J Gastroenterol. 2015;21:1158–1166.PubMedPubMedCentralCrossRef You SC, Kim KJ, Kim SU et al. Factors associated with significant liver fibrosis assessed using transient elastography in general population. World J Gastroenterol. 2015;21:1158–1166.PubMedPubMedCentralCrossRef
41.
Zurück zum Zitat Kim D, Konyn P, Sandhu KK, Dennis BB, Cheung AC, Ahmed A. Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States. J Hepatol. 2021;75:1284–1291.PubMedCrossRef Kim D, Konyn P, Sandhu KK, Dennis BB, Cheung AC, Ahmed A. Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States. J Hepatol. 2021;75:1284–1291.PubMedCrossRef
42.
Zurück zum Zitat Alqahtani SA, Paik JM, Biswas R, Arshad T, Henry L, Younossi ZM. Poor awareness of liver disease among adults with NAFLD in the United States. Hepatol Commun. 2021;5:1833–1847.PubMedPubMedCentralCrossRef Alqahtani SA, Paik JM, Biswas R, Arshad T, Henry L, Younossi ZM. Poor awareness of liver disease among adults with NAFLD in the United States. Hepatol Commun. 2021;5:1833–1847.PubMedPubMedCentralCrossRef
43.
Zurück zum Zitat Cusi K, Isaacs S, Barb D et al. American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD). Endocr Pract. 2022;28:528–562.PubMedCrossRef Cusi K, Isaacs S, Barb D et al. American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD). Endocr Pract. 2022;28:528–562.PubMedCrossRef
44.
Zurück zum Zitat Younossi ZM, Ong JP, Takahashi H et al. A global survey of physicians knowledge about nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2022;20:e1456–e1468.PubMedCrossRef Younossi ZM, Ong JP, Takahashi H et al. A global survey of physicians knowledge about nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2022;20:e1456–e1468.PubMedCrossRef
45.
Zurück zum Zitat Unalp-Arida A, Ruhl CE. Liver fibrosis scores predict liver disease mortality in the United States population. Hepatology. 2017;66:84–95.PubMedCrossRef Unalp-Arida A, Ruhl CE. Liver fibrosis scores predict liver disease mortality in the United States population. Hepatology. 2017;66:84–95.PubMedCrossRef
46.
Zurück zum Zitat Ford ES, Li C, Zhao G, Pearson WS, Tsai J, Churilla JR. Sedentary behavior, physical activity, and concentrations of insulin among US adults. Metabolism. 2010;59:1268–1275.PubMedCrossRef Ford ES, Li C, Zhao G, Pearson WS, Tsai J, Churilla JR. Sedentary behavior, physical activity, and concentrations of insulin among US adults. Metabolism. 2010;59:1268–1275.PubMedCrossRef
47.
Zurück zum Zitat Stockwell S, Trott M, Tully M et al. Changes in physical activity and sedentary behaviours from before to during the COVID-19 pandemic lockdown: A systematic review. BMJ Open Sport Exerc Med. 2021;7:e000960.PubMedCrossRef Stockwell S, Trott M, Tully M et al. Changes in physical activity and sedentary behaviours from before to during the COVID-19 pandemic lockdown: A systematic review. BMJ Open Sport Exerc Med. 2021;7:e000960.PubMedCrossRef
Metadaten
Titel
Prepandemic Prevalence Estimates of Fatty Liver Disease and Fibrosis Defined by Liver Elastography in the United States
verfasst von
Aynur Unalp-Arida
Constance E. Ruhl
Publikationsdatum
29.09.2022
Verlag
Springer US
Erschienen in
Digestive Diseases and Sciences / Ausgabe 4/2023
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-022-07707-1

Weitere Artikel der Ausgabe 4/2023

Digestive Diseases and Sciences 4/2023 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.